DrugPatentWatch Database Preview
Eravacycline dihydrochloride - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for eravacycline dihydrochloride and what is the scope of patent protection?
Eravacycline dihydrochloride
is the generic ingredient in one branded drug marketed by Tetraphase Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Eravacycline dihydrochloride has seventy patent family members in thirty countries.
Summary for eravacycline dihydrochloride
| International Patents: | 70 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 10 |
| DailyMed Link: | eravacycline dihydrochloride at DailyMed |
Recent Clinical Trials for eravacycline dihydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tetraphase Pharmaceuticals, Inc. | Phase 3 |
| Tetraphase Pharmaceuticals, Inc. | Phase 1 |
| Department of Health and Human Services | Phase 1 |
US Patents and Regulatory Information for eravacycline dihydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-002 | Jun 3, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for eravacycline dihydrochloride
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | PI0916985 | Start Trial |
| Lithuania | C2323972 | Start Trial |
| Serbia | 53003 | Start Trial |
| Taiwan | 201538483 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for eravacycline dihydrochloride
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2323972 | CA 2019 00009 | Denmark | Start Trial | PRODUCT NAME: ERAVACYCLIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1312 20180209 |
| 2323972 | 19C1012 | France | Start Trial | PRODUCT NAME: ERAVACYCLINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/18/1312 20180924 |
| 2323972 | 122019000024 | Germany | Start Trial | PRODUCT NAME: ERAVACYCLINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1312 20180920 |
| 2323972 | 2019010 | Norway | Start Trial | PRODUCT NAME: ERAVASYKLIN ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV; REG. NO/DATE: EU/1/18/1312 20181025 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
